ClinicalTrials.gg
TerminatedNCT05359081Updated Mar 19, 2025

A Clinical Trial to Evaluate the Long-term Safety and Tolerability of SEP-363856 in Patients With Schizophrenia in Japan

A Phase 3 interventional study of SEP-363856 in Schizophrenia, sponsored by Sumitomo Pharma Co., Ltd.. Terminated at 51 sites in Japan. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2025-03-19.

Sponsored by Sumitomo Pharma Co., Ltd. · Phase 3, Interventional, and Treatment

Why this study was terminated
Due to company business strategy

From the registry’s dates

  • Primary completion was Mar 2024, 2 years 7 months ago, and no results have been posted to the registry; the sponsor requested a delay in submitting them in Mar 2025.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
68
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies testing SEP-363856 in Schizophrenia — 1 open to participants now, 2 under way, 2 of them phase 3. SEP-363856 · Schizophrenia.

Enrollment
14th of 23
68 · median 83
Started
2022
with 4 others
Phase 3
9 of 23
1 open now
Registered
15th of 23
by date
Lead sponsor
4 of 23
Sumitomo Pharma Co., Ltd.

Among the 23 studies testing SEP-363856 in Schizophrenia, this one is the 14th largest by enrollment, is one of 5 that started in 2022, is one of 9 in phase 3, and was the 15th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

1 of the 23 studies testing SEP-363856 in Schizophrenia is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About SEP-363856

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing SEP-363856 in Schizophrenia, or all of them as a file.
02

Study summary

A clinical study to investigate the long-term safety and torelability of SEP-363856 in clinically stable adult patients with schizophrenia in Japan.

Read the detailed description

A phase 3, 52-week, open-label study to evaluate the long-term safety and tolerability of SEP-363856 in patients with schizophrenia in Japan. Participants will take flexible dose of SEP-363856 (50 mg/day and 75 mg/day) every night at bedtime for 52 weeks in an open-label manner.

03

Conditions studied

  • Schizophrenia

Browse trials for

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Must be fully informed of and understand the objectives, procedures, and possible benefits and risks of the study, and give written prior to performing any study related activities.
  2. Male or female between 18 to 65 years of age (inclusive) at the time of consent.
  3. Must meet DSM 5 criteria for schizophrenia as established by clinical interview at Screening
  4. Must have a PANSS total score >=60 at Screening and Baseline.
  5. Must have a CGI-S score >=3 at Screening and Baseline
  6. Judged to be clinically stable (i.e., no evidence of an acute exacerbation) by the Investigator for at least 8 weeks prior to Baseline and has had no change in antipsychotic medication(s) (minor dose adjustments for tolerability purposes are permitted) for at least 6 weeks prior to Screening
  7. In the opinion of the Investigator, subjects must be generally healthy based on Screening medical history, physical examination, vital signs, , and clinical laboratory values (hematology, chemistry, and urinalysis).

Exclusion criteria

Exclusion Criteria:

  1. Have a diagnosis or presence of symptoms consistent with a DSM-5 diagnosis other than schizophrenia. Exclusionary disorders include but are not limited to alcohol use disorder or substance (other than nicotine or caffeine) use disorder within past 12 months or for a total of >= 10 years during the subject's lifetime, major depressive disorder, bipolar I or II disorder, schizoaffective disorder, obsessive compulsive disorder, and posttraumatic stress disorder. Symptoms of mild to moderate mood dysphoria or anxiety are allowed so long as these symptoms have not been a focus of primary treatment
  2. At significant risk of harming self, others, or objects based on Investigator's judgment.
  3. Have any unstable medical condition or any clinically significant chronic disease that in the opinion of the Investigator, would limit the subject's ability to complete and/or participate in the study.
  4. Female subjects who are pregnant or lactating.
  5. Have any clinically significant abnormal laboratory value(s) at Screening (hematology, chemistry, and urinalysis) as determined by the Investigator.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
68 participants (actual)

Study arms

  • Experimental
    SEP-363856

    SEP-363856 (50 or 75 mg/day, flexible dose)

    Drug: SEP-363856

Interventions

  • SEP-363856 50 mg or 75 mg, flexibly dosed once daily tablet for 52 weeks

06

What researchers measure

Primary outcomes

  1. The incidence of overall adverse events (AEs), serious adverse events (SAEs), and AEs leading to discontinuation.

    Evaluate the long-term safety and tolerability of flexible dosed SEP-363856 (50 and 75 mg/day) in subjects with schizophrenia by the incidence of overall adverse events (AEs), serious AEs (SAEs), and AEs leading to discontinuation.

    Time frame: Week 52

07

Study locations

51 sites
  • Hotei Hospital
    Konan-shi, Aichi, Japan
  • Heart Care Clinic Omachi
    Akita-shi, Akita, Japan
  • Seinan Hospital
    Hachinohe-shi, Aomori, Japan
  • Ishigooka Hospital
    Chiba-shi, Chiba, Japan
  • Kohnodai Hospital National Center for Global Health and Medicine
    Ichikawa-shi, Chiba, Japan
  • Fukui Hospital
    Fukui-shi, Fukui, Japan
  • Ai Sakura Clinic
    Fukuoka-shi, Fukuoka, Japan
  • Inokuchi Noma Hospital
    Fukuoka-shi, Fukuoka, Japan
  • Kuramitsu Hospital
    Fukuoka-shi, Fukuoka, Japan
  • Medical corporation Shinseikai Kaku Mental Clinic
    Fukuoka-shi, Fukuoka, Japan
  • Mental Clinic Sakurazaka
    Fukuoka-shi, Fukuoka, Japan
  • Shiranui Hospital
    Omuta-shi, Fukuoka, Japan
  • Takeda General Hospital
    Aizuwakamatsu-shi, Fukushima, Japan
  • Medical Corporation Kishikai Kishi Hospital
    Kiryu-shi, Gunma, Japan
  • Hayakawa Clinic
    Kure-shi, Hiroshima, Japan
  • NHO Kure Medical Center and Chugoku Cancer Center
    Kure-shi, Hiroshima, Japan
  • Goryokai Hospital
    Sapporo-shi, Hokkaido, Japan
  • Tatsuta Clinic
    Chuo-ku, Kobe-shi, Hyogo, Japan
  • Kishiro Mental Clinic
    Kawasaki-shi, Kanagawa, Japan
  • Musashikosugi J Kokorono Clinic
    Kawasaki-shi, Kanagawa, Japan
  • Hino Hospital
    Yokohama-shi, Kanagawa, Japan
  • Miki Mental Clinic
    Yokohama-shi, Kanagawa, Japan
  • Yamatenomori Kokorono Clinic
    Yokohama-shi, Kanagawa, Japan
  • Tosa Hospital
    Kochi-shi, Kochi, Japan
  • Kouyoudai Hospital
    Kumamoto-shi, Kumamoto, Japan
  • Satokai Yuge Hospital
    Kumamoto-shi, Kumamoto, Japan
  • Miyazaki Prefectural Miyazaki Hospital
    Miyazaki-shi, Miyazaki, Japan
  • Ozawa Mental Clinic
    Matsumoto-shi, Nagano, Japan
  • Okayama Psychiatric Medical Center
    Okayama-shi, Okayama, Japan
  • NHO Ryukyu Hospital
    Kunigami-gun, Okinawa, Japan
  • Akari Clinic
    Naha-shi, Okinawa, Japan
  • Miebashi Clinic
    Naha-shi, Okinawa, Japan
  • Barclay Imuro Mental Clinic
    Urasoe-shi, Okinawa, Japan
  • Shiroma Clinic
    Urasoe-shi, Okinawa, Japan
  • Kansai Medical University Medical Center
    Moriguchi-shi, Osaka, Japan
  • Keihan Hospital
    Moriguchi-shi, Osaka, Japan
  • NHO Hizen Psychiatric Center
    Kanzaki-gun, Saga, Japan
  • Rainbow & Sea Hospital
    Karatsu-shi, Saga, Japan
  • Inuo Mental Care Hospital
    Tosu-shi, Saga, Japan
  • Nishi Kumagaya Hospital
    Kumagaya-shi, Saitama, Japan
  • Mental Clinic Minami
    Saitama-shi, Saitama, Japan
  • Ryokuwakai Stresscare Hibiya Clinic
    Chiyoda-ku, Tokyo, Japan
  • Murakami Hospital
    Edogawa-ku, Tokyo, Japan
  • Narimasu Kosei Hospital
    Itabashi-ku, Tokyo, Japan
  • Senzoku Psychosomatic Medicine Clinic
    Meguro-ku, Tokyo, Japan
  • Sakura-shinmachi Mental Clinic
    Setagaya-ku, Tokyo, Japan
  • Sangenjaya Neurology- Psychosomatic Clinic
    Setagaya-ku, Tokyo, Japan
  • Sangubashi Kokorono Clinic
    Shibuya-ku, Tokyo, Japan
  • Ohwa Mental Clinic
    Toshima-ku, Tokyo, Japan
  • Sanyo Hospital
    Sakata-shi, Yamagata, Japan
  • Yamagata Sakuracho Hospital
    Yamagata-shi, Yamagata, Japan
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2022 to primary completion in Mar 2024, 22 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 27, 2022
First posted
May 3, 2022
StartActual
May 16, 2022
Primary completionActual
Mar 21, 2024
CompletionActual
Mar 28, 2024
Results delay requested
Mar 16, 2025
Last update
Mar 19, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 19, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05359081
Responsible party
Sponsor
First posted
May 3, 2022
Start date
May 16, 2022
Primary completion
Mar 21, 2024
Completion
Mar 28, 2024
Last update
Mar 19, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: SEP-363856

Start the discussion